Join the CRISPR revolutionReason to invest in NASDAQ:NTLA and NASDAQ:BEAM
Groundbreaking CRISPR Tech.
Promising Treatment Pipeline.
Big Pharma Partnerships.
Positioned to make a significant difference in healthcare.
Next report date
Report period
Q1 2024
EPS estimate
−1.28EUR
Revenue estimate
10.42 MEUR
−4.908EUR
−435.96 MEUR
32.87 MEUR
94.19 M
About Intellia Therapeutics, Inc.
Sector
Industry
CEO
John M. Leonard
Website
Headquarters
Cambridge
Employees (FY)
526
Founded
2014
FIGI
BBG00CW7Q762
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
NTLA shortThis is only my second published idea and my last published trade was successful so with 100% accuracy the probability that this is going to pan out the way I want is infintesimal.
Here goes anyways. This is at what I would consider a key level of resistance permitting for a tight stop loss but de
Biotechs Are Dangerous, But NTLA has Little resistance Over 55Many biotechs are trying to "turn the corner". Over 55 and NTLA could much higher. I am going to look at bullish call spread ideas this week.
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA
Chart Overview 03/28/22
Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tr
Intellia devolving. NTLAGoals 61, 53. Invalidation at 110.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fra
$NTLA back into the channelWe lost 89.95 so looks like we're gonna be bouncing around the channel again. Bottom of the channel is 51.11 so it may wanna wait before playing calls.
NTLA : SWING TRADEIntellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 9
12/19/21 NTLAIntellia Therapeutics, Inc. ( NASDAQ:NTLA )
Sector: Health Technology (Biotechnology)
Market Capitalization: 9.545B
Current Price: $128.23
Breakout price: $125.25 (hold above)
Buy Zone (Top/Bottom Range): $118.80-$110.25
Price Target: $170.00-$174.00
Estimated Duration to Target: 84-90d
Contract
NTLANot the best option possible, but the rebound that occurred is interesting. We "held" the trend during the week, as well as 50%, formally a large hidden . There may be an increase in the fact of holding the blue level.
11/ 05 /21 Oppenheimer Supports Performance 145,0
11/ 05 /21 HC Wainwright & Co.
NLTA: Should be heading to retest recent high of $200Healthcare sector seems bullish overall. Lots of stocks within this sector have bullish bias as well.
NTLA have a pretty well defined ABCDE Triangle pattern, and any time now is a good time to enter.
Stop loss below the low of C i.e. around $140.
Disclaimer: I'm not giving any trading and investi
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where 38I is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange INTELLIA THERAPEUTICS INC. stocks are traded under the ticker 38I.
INTELLIA THERAPEUTICS INC. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
38I earnings for the last quarter are −1.31 EUR per share, whereas the estimation was −1.42 EUR resulting in a 7.91% surprise. The estimated earnings for the next quarter are −1.30 EUR per share. See more details about INTELLIA THERAPEUTICS INC. earnings.
INTELLIA THERAPEUTICS INC. revenue for the last quarter amounts to 11.34 M EUR despite the estimated figure of 12.34 M EUR. In the next quarter revenue is expected to reach 11.55 M EUR.
Yes, you can track INTELLIA THERAPEUTICS INC. financials in yearly and quarterly reports right on TradingView.
38I net income for the last quarter is −119.74 M EUR, while the quarter before that showed −115.62 M EUR of net income which accounts for −3.56% change. Track more INTELLIA THERAPEUTICS INC. financial stats to get the full picture.
No, 38I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 38I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTELLIA THERAPEUTICS INC. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 526.00 employees. See our rating of the largest employees — is INTELLIA THERAPEUTICS INC. on this list?
We've gathered analysts' opinions on INTELLIA THERAPEUTICS INC. future price: according to them, 38I price has a max estimate of 135.53 EUR and a min estimate of 22.59 EUR. Read a more detailed INTELLIA THERAPEUTICS INC. forecast: see what analysts think of INTELLIA THERAPEUTICS INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTELLIA THERAPEUTICS INC. EBITDA is −458.73 M EUR, and current EBITDA margin is −1.40 K%. See more stats in INTELLIA THERAPEUTICS INC. financial statements.